Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Cited by (774)

Items 601–700 of 774

1. Histone Deacetylase (HDAC) Inhibitors in Recent Clinical Trials for Cancer Therapy
   Kristina Keller, Manfred Jung · 2013 · Springer eBooks
2. The regulatory mechanisms and treatment of HDAC6 in immune dysregulation diseases
   Yanyang Liang, Ying Wang, Jianxiao Xing, Junqin Li, Kaiming Zhang · 2025 · Frontiers in Immunology
3. The Future of Epigenetics: Emerging Technologies and Clinical Applications
   Kavita A. Iyer, Rumiana Tenchov, Janet M. Sasso, Trupti Thite, Yi Deng, Qiongqiong Angela Zhou · 2026 · ACS Pharmacology & Translational Science
4. [Research Progress of Epigenetics in Pathogenesis and Treatment of Malignant Tumors].
   Pan Wang, Honglin Zhao, Fan Ren, Qingchun Zhao, Ruifeng Shi, Xingyu Liu, Jinghao Liu, Li Y, Ying Li, Hongyu Liu et al. · 2020 · Europe PMC (PubMed Central)
5. The role of CUDC‐907, a dual phosphoinositide‐3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T‐cell leukemia
   Chie Ishikawa, Naoki Mori · 2020 · European Journal Of Haematology
6. 4-Phenylbutyric acid attenuates amyloid-β proteotoxicity through activation of HSF-1 in an Alzheimer's disease model of the nematode Caenorhabditis elegans
   Stefan Baumanns, Felix Muehlemeyer, Laura C. Miesbauer, Jonas Baake, Eva M. Roloff, Daniel M. Beis, Uwe Wenzel · 2023 · Biochemical and Biophysical Research Communications
7. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma
   Donald C. Moore, Justin R. Arnall, Robert Donald Harvey · 2018 · Journal of Oncology Pharmacy Practice
8. Class 1 HDAC and HDAC 6 inhibition inversely regulates CD 38 induction in myeloma cells via interferon‐α and ATRA
   Ariunzaya Bat‐Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa et al. · 2018 · British Journal of Haematology
9. Current status of agents active against the T315I chronic myeloid leukemia phenotype
   Aine Carol Burke, Ronan T. Swords, Kevin R. Kelly, Francis Joseph Giles · 2011 · Expert Opinion on Emerging Drugs
10. Inhibiteurs des histone-désacétylases : la régulation épigénétique sort de l’ombre
    Nicolas Pécuchet, Thomas Cluzeau, Constance Thibault, Nicolas Mounier, Stéphane Vignot · 2010 · Bulletin du Cancer
11. Ultrasonic Atomizer-Driven Development of Biocompatible and Biodegradable Poly( d , l -lactide-co-glycolide) Nanocarrier-Encapsulated Suberoylanilide Hydroxamic Acid to Combat Brain Cancer
    Jaspreet Kaur, Shweta Jakhmola, Ravi Raj Singh, Bhavana Joshi, Hem Chandra Jha, Abhijeet Joshi · 2021 · ACS Applied Bio Materials
12. HDAC Inhibition in Cancer Therapy: An Increasingly Intriguing Tale of Chemistry, Biology and Clinical Benefit
    Peter ten Holte, Kristof Van Emelen, Michel Janicot, Peter C.C. Fong, Johann Sebastian De Bono, Janine Arts · 2007 · Topics in medicinal chemistry
13. Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy
    Jiyong Wu, Jing Nie, Yepeng Luan, Yanjiao Ding · 2022 · Current Medicinal Chemistry
14. Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker
    Adam Louis Cohen, Leigh A. Neumayer, Kenneth M. Boucher, Rachel E. Factor, Gajendra Shrestha, Mark L. Wade, John G. Lamb, Kylee Arbogast, Stephen Piccolo, Joanna Riegert et al. · 2017 · JCO Precision Oncology
15. Hsp90 regulates HDAC3-dependent gene transcription while HDAC3 regulates the functions of Hsp90
    Akhil Kotwal, Sreedhar Amere Subbarao · 2020 · Cellular Signalling
16. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status
    Tae Hyun Kim, Choung‐Soo Kim, Je‐Hwan Lee, Se Jin Jang, Jung Jin Hwang, Seonggu Ro, Young‐Lan Hyun, Jene Choi · 2010 · Breast Cancer Research and Treatment
17. Histone Deacetylase Inhibitors in Combinations: Will the Preclinical Promises Be Kept?
    Susan Elaine Bates, Richard Piekarz · 2007 · The Cancer Journal
18. Role of Additional Novel Therapies in Myeloproliferative Neoplasms
    Warren C. Fiskus, Siddhartha Ganguly, Suman Kambhampati, Kapil N. Bhalla · 2012 · Hematology/Oncology Clinics of North America
19. Design, Synthesis, Bioactivity Evaluation, Crystal Structures, and In Silico Studies of New α-Amino Amide Derivatives as Potential Histone Deacetylase 6 Inhibitors
    Yangrong Xu, H. Tang, YiJie Xu, Jialin Guo, Xu Zhao, Qingguo Meng, Junhai Xiao · 2022 · Molecules
20. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia
    Simon Kavanagh, Aisling Nee, Jeffrey Howard Lipton · 2018 · Expert Opinion on Emerging Drugs
21. Histone deacetylase 6 expression in metastatic lymph nodes is a valuable prognostic marker for resected node-positive esophageal squamous cell cancer
    Xuan Xie, Kongjia Luo, Yi Li, Yihong Ling, Shuishen Zhang, Xiuying Xie, Jing Wen · 2018 · Cancer Management and Research
22. Histone Deacetylase Inhibitors in Cancer Prevention and Therapy
    Shahrzad Movafagh, Amanda M. Munson · 2019 · Elsevier eBooks
23. Improved Anticancer Activities of a New Pentafluorothio-Substituted Vorinostat-Type Histone Deacetylase Inhibitor
    Nils Goehringer, Yayi Peng, Bianca Nitzsche, Hannah Biermann, Rohan Pradhan, Rainer Schobert, Marco Herling, Michael Höpfner, Bernhard Biersack · 2021 · Pharmaceuticals
24. Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells
    Laurence A. Booth, Jane L. Roberts, John M. Kirkwood, Andrew Stewart Poklepovic, Paul Dent · 2018 · Advances in cancer research
25. HDAC6 inhibition ameliorates sensory hypersensitivity and reduces immune cell signatures in the dorsal root ganglia in murine chronic pain models
    Ilinca M. Giosan, Randal A. Serafini, Aarthi Ramakrishnan, Madden J. Tuffy, Jeffrey H. Zimering, Alexandru Babeș, Li Shen, Venetia Zachariou · 2025 · Molecular Pharmacology
26. Identification of a chaperone-code responsible for Rad51-mediated genome repair
    Khushboo Rani, Akanksha Gotmare, Andreas Maier, Ruchira Menghal, Nashat Akhtar, Nupur Fangaria, Johannes Büchner, Sunanda Bhattacharyya · 2024 · Journal of Biological Chemistry
27. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma
    Syed Farhan Zafar, Ganji Purnachandra Nagaraju, Bassel F. El‐Rayes · 2012 · Expert Opinion on Therapeutic Targets
28. Epigenetic Modulation in Hematologic Malignancies: Challenges and Progress
    Constantine S. Mitsiades, Kenneth Carl Anderson · 2009 · Journal of the National Comprehensive Cancer Network
29. The Emerging Role of Histone Deacetylases (HDACs) in UPR Regulation
    Soumen Kahali, Bhaswati Sarcar, Prakash Chinnaiyan · 2011 · Methods in enzymology on CD-ROM/Methods in enzymology
30. Epigenetics of Prostate Cancer and the Prospect of Identification of Novel Drug Targets by RNAi Screening of Epigenetic Enzymes
    Mari L. Björkman, Juha Rantala, Matthias Nees, Olli Kallioniemi · 2010 · Epigenomics
31. Differences in Functional Expression of Connexin43 and NaV1.5 by Pan- and Class-Selective Histone Deacetylase Inhibition in Heart
    Xian Zhang, Dakshesh Patel, Qin Xu, Richard D. Veenstra · 2018 · International Journal of Molecular Sciences
32. Identification of a histone deacetylase inhibitor as a therapeutic candidate for congenital central hypoventilation syndrome
    Chiara Africano, Tiziana Bachetti, Paolo Uva, Gabriel Pitollat, Genny Del Zotto, Francesca Giacopelli, Giada Recchi, Nicolas Lenfant, Amélia Madani, Nathan Beckouche et al. · 2024 · Molecular Therapy — Nucleic Acids
33. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents
    Andrea Uecker, Marit Sicker, Thomas L. Beckers, Siavosh Mahboobi, Daniel Hägerstrand, Arne Östman, Frank‐D. Böhmer · 2010 · Anti-Cancer Drugs
34. Downregulation of androgen receptors by NaAsO2 via inhibition of AKT‐NF‐κB and HSP90 in castration resistant prostate cancer
    Yunlim Kim, Sang-Eun Park, Jeong‐Weon Moon, B.-M. Kim, Ha‐Gyeong Kim, In Gab Jeong, Sangjun Yoo, Jae Beom Ahn, Dalsan You, Jhang Ho Pak et al. · 2017 · The Prostate
35. The Potential of Histone Deacetylase Inhibitors in Lung Cancer
    Ana M. Aparicio · 2006 · Clinical Lung Cancer
36. Design, synthesis, and biological evaluation of aminopyrazine-based ATR/HDACs dual inhibitors
    Yinghui Yuan, Chenchen Wang, Ji‐Long Duan, Pengpeng Zhang, Meng-Lan He, Zhen Liu, Zi Hui, Xiang‐Yang Ye · 2025 · Molecular Diversity
37. Antigenic Dark Matter: Unexplored Post-Translational Modifications of Tumor-Associated and Tumor-Specific Antigens in Pancreatic Cancer
    Amin Safa, Idris Vruzhaj, Marta Gambirasi, Giuseppe Toffoli · 2025 · Cancers
38. Augmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells
    Saowaluk Saisomboon, Ryusho Kariya, Panupong Mahalapbutr, Tonkla Insawang, Kanlayanee Sawanyawisuth, Ubon Cha’on, Thanyada Rungrotmongkol, Sopit Wongkham, Sarawut Jitrapakdee, Seiji Okada et al. · 2024 · International Journal of Molecular Sciences
39. Pharmacoepigenetics of Histone Deacetylase Inhibitors in Cancer
    Nikolaos Garmpis, Christos Damaskos, Anna Garmpi, Serena I. Valsami, Dimitrios Dimitroulis · 2019 · Elsevier eBooks
40. Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824
    Maria V. Yusenko, Karl‐Heinz Klempnauer · 2021 · BBA Advances
41. MOF negatively regulates estrogen receptor α signaling via CUL4B-mediated protein degradation in breast cancer
    Xu Zhang, Yang Yang, Danyang Li, Zhen Wu, Haoyu Liu, Ziyan Zhao, Hongying Zhu, Fei Xie, Xiangzhi Li · 2022 · Frontiers in Oncology
42. Machine Learning Approaches to Predict the Selectivity of Compounds against HDAC1 and HDAC6
    Berna Doğan · 2024 · Journal of Computational Biophysics and Chemistry
43. Finding the place of histone deacetylase inhibitors in prostate cancer therapy
    D.L. Marrocco, Margaret M. Centenera, Howard I. Scher, Wayne D. Tilley, Lisa M. Butler · 2009 · Expert Review of Clinical Pharmacology
44. Exploiting Cancer Dependence on Molecular Chaperones
    Swee Y. Sharp, Keith Jones, Paul Workman · 2014 · Elsevier eBooks
45. The Next Generation of Therapies for Chronic Myeloid Leukemia
    Alfonso Quintás‐Cardama, Jörge E. Cortes · 2009 · Clinical Lymphoma & Myeloma
46. Novel nuclear role of HDAC6 in prognosis and therapeutic target for colorectal cancer
    Daniel J. García-Domínguez, Lourdes Hontecillas‐Prieto, Maciej A. Kaliszczak, Miaomiao He, Miguel Ángel Burguillos, Rajaa El Bekay, Vahitha B. Abdul‐Salam, Combiz Khozoie, Khalid Shah, Kevin O’Neill et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
47. Targeting Oncogenic Activity and Signalling of Mutant Receptor Tyrosine Kinase FLT3
    Boban Dobrevski, Hannah Willems, Carolin Lossius, Jörg P. Müller · 2025 · Cancers
48. Design and Synthesis of c-Met and HDAC Dual Inhibitors for the Treatment of Breast Cancer
    Zuoyang Wang, Zhichao Shi, Shiqi Yang, Zizhou Niu, Kaifei Shu, Linbo Chen, Cailian Zhi, Funian Liu, Wenjun Huang, Tingting Fan et al. · 2024 · ACS Medicinal Chemistry Letters
49. A Triple combination formulation of an HDAC inhibitor treats chronic pain in rodent spared nerve injury model
    Maria Virginia Centeno, Md. Suhail Alam†, Kasturi Haldar, A. Vania Apkarian · 2025 · Journal of Pain
50. Cleavage of HSP90β induced by histone deacetylase inhibitor and proteasome inhibitor modulates cell growth and apoptosis
    Sangkyu Park, Jae-Hyung Jeon, Jeong-A Park, Jun-Kyu Choi, Younghee Lee · 2020 · Cell Stress and Chaperones
51. Sulfhydryl-Reactive Phytochemicals as Dual Activators of Transcription Factors NRF2 and HSF1
    Albena T. Dinkova‐Kostova, Ying Zhang, Sharadha Dayalan Naidu, Rumen V. Kostov, Ashley Pheely, Vittorio Calabrese · 2013 · Springer eBooks
52. Transcription Factors as Therapeutic Targets in Lymphoid Malignancies
    Takaomi Sanda · 2007 · International Reviews of Immunology
53. HSP90-specific inhibitor, PSY-2–12, ameliorates cellular senescence via activating autophagy: A potential senotherapeutic target against acute kidney injury
    Thuy Quynh Nhu Nguyen, Ai-Han Nguyen, Manh Quoc Dao, Mi Kyung Kim, Thi Tuyet Mai Pham, Seojin Kim, Ji Hae Seo, Young Ho Seo, Eunyoung Ha · 2025 · Biochemical Pharmacology
54. Flavonoid-Based Derivatives for Modulating Various Targets of Alzheimer’s Disease
    Jyoti Pandey · 2023 · Springer eBooks
55. In‐solution structure and oligomerization of human histone deacetylase 6 – an integrative approach
    Shivam Shukla, Jan Komárek, Zora Nováková, Jana Nedvědová, Kseniya Ustinova, Pavla Vaňková, Alan Kádek, Charlotte Uetrecht, Haydyn D. T. Mertens, Cyril Bařinka · 2022 · FEBS Journal
56. Contribution of HSP90 Cleavage to the Cytotoxic Effect of Suberoylanilide Hydroxamic Acid In Vivo and the Involvement of TXNIP in HSP90 Cleavage
    Sangkyu Park, Dongbum Kim, Haiyoung Jung, Inpyo Choi, Hyung‐Joo Kwon, Younghee Lee · 2023 · Biomolecules & Therapeutics
57. Design, synthesis, insilco study and biological evaluation of new isatin-sulfonamide derivatives by using mono amide linker as possible as histone deacetylase inhibitors
    Ammar Abdul Aziz Alibeg, Mohammed Hassan Mohammed · 2024 · Polski Merkuriusz Lekarski
58. Targeting Mantle Cell Lymphoma with a Strategy of Combined Proteasome and Histone Deacetylase Inhibition
    Michael Batalo, Prithviraj Bose, Beata Holkova, Steven Grant · 2014 · Resistance to targeted anti-cancer therapeutics
59. Effect of HDAC Inhibitors on Corneal Keratocyte Mechanical Phenotypes in 3-D Collagen Matrices.
    Vindhya Koppaka, Neema Lakshman, W. Matthew Petroll · 2015 · Europe PMC (PubMed Central)
60. Hyperthermia and Pharmacological Intervention of Heat Shock Proteins in Anticancer Treatments
    Amere Subbarao Sreedhar · 2006 · Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
61. Histone Deacetylase Inhibitors in Multiple Myeloma
    Teru Hideshima · 2008 · Humana Press eBooks
62. The Construction of ceRNA Regulatory Network Unraveled Prognostic Biomarkers and Repositioned Drug Candidates for the Management of Pancreatic Ductal Adenocarcinoma
    Büşra Aydın, Keziban Okutan, Ozge Onluturk Aydogan, Raghu Sinha, Beste Turanlı · 2025 · Current Issues in Molecular Biology
63. The Dual Histone Deacetylase-Proteasome Inhibitor RTS-V5 Acts Synergistically With Ritonavir to Induce Endoplasmic Reticulum Stress in Bladder Cancer Cells
    Kazuki Okubo, Nina Reßing, Wolfgang A. Schulz, Finn Kristian Hansen, Takako Asano, Akinori Sato · 2021 · Anticancer Research
64. HDAC inhibitor and proteasome inhibitor induce cleavage and exosome-mediated secretion of HSP90 in mouse pluripotent stem cells
    Jun-Kyu Choi, Sangkyu Park, Jeong-A Park, Ha-Eun Shin, Yeram Choi, Younghee Lee · 2022 · Biochemical and Biophysical Research Communications
65. The Role of Histone Deacetylases in Neurodegenerative Diseases and Small-Molecule Inhibitors as a Potential Therapeutic Approach
    Roland W. Bürli, Elizabeth A. Thomas, Vahri Beaumont · 2010 · Topics in medicinal chemistry
66. Current perspective of histone deacetylase inhibitors: A review
    Bhavini K Gharia, Jagatkumar Upadhyay, Bhanubhai N. Suhagia, Shailesh Amritlal Shah · 2018 · International Journal of Pharmaceutical Chemistry and Analysis
67. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression
    Bo Zhang, Yan Wang, Xueli Pang · 2010 · Medical Oncology
68. Epigenetic Targets in Drug Discovery: Cell‐Based Assays for HDAC Inhibitor Hit Validation
    Mira Jung, Kwon‐Jeong Yong, Alfredo Velena, Sung Lee · 2009 · Methods and principles in medicinal chemistry
69. Machine learning approaches to quantitively predict selectivity of compounds against hDAC1 and hDAC6 isoforms
    Berna Doğan · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
70. Selective Disposal of Insoluble Protein Aggregates
    Pierfausto Seneci · 2015 · Elsevier eBooks
71. Novel Nitrogen Heterocycle–Hydroxamic Acid Conjugates Demonstrating Potent Anti-Acute Lymphoblastic Leukemia Activity: Induction of Endogenous Apoptosis and G0/G1 Arrest via Regulation of Histone H3 Acetylation and AKT Phosphorylation in Jurkat Cells
    Lingjie Wu, Zhao Li, Liping Wang, Yi Lu, Gaojie Lou, Bin Zhang, Ning Wang · 2025 · Cells
72. A comprehensive review on azole-based hydroxamic acid analogs as histone deacetylases (HDACs) inhibitors
    Deepali Shukla, Balaji Wamanrao Matore, Anjali Murmu, Pragya Gawande, Partha Pratim Roy, Jagadish Singh · 2025 · Future Medicinal Chemistry
73. Epigenetic Regulation of Myeloma Within Its Bone Marrow Microenvironment
    Elke De Bruyne, Ken Maes, Sarah Deleu, Els Van Valckenborgh, Eline Menu, Isabelle Vande Broek, Joanna Fraczek, Leo A. van Grunsven, Vera Rogiers, Helena Jernberg‐Wiklund et al. · 2012 · Springer eBooks
74. The Molecular Biology of Kidney Cancer and Its Clinical Translation into Treatment Strategies
    William G. Kaelin, Daniel J. George · 2009 · Humana Press eBooks
75. Histone deacetylase inhibitors
    Paul A. Marks · 2013 · Cambridge University Press eBooks
76. HDAC6-HSP90 pathway-mediated protein folding and degradation regulates tumor cell proliferation and metastasis
    Rui Tian, Xiaoyu Yan, Sihang Yu, Long Xu, Yuanxin Zhao, Liankun Sun, Jing Su · 2020 · Chinese Science Bulletin (Chinese Version)
77. Clinical Applications of HDAC Inhibitors as Anticancer Agents in Prostate, Breast, Ovarian, and Cervical Cancers
    Saad Bakrim, Farah Atifi, Nasreddine El Omari, Younes Zaid, Tarik Aanniz, Learn−Han Lee, Gökhan Zengin, Abdelhakim Bouyahya · 2025 · ChemistrySelect
78. HSP90 Inhibition as an Anticancer Strategy: Novel Approaches and Future Directions
    Marissa V. Powers, Paul Workman · 2009 · Springer eBooks
79. HSP90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
    Swee Y. Sharp, Keith Jones, Paul Workman · 2008 · Elsevier eBooks
80. HDAC6 Regulation of Androgen Signaling in Prostate Cancer
    Junkui Ai, Zhou Wang · 2013 · Springer eBooks
81. Extracellular HSP90 in Cancer Invasion and Metastasis: From Translational Research to Clinical Prospects
    Dimitra Thomaidou, Evangelia Patsavoudi · 2015 · Journal of Analytical Oncology
82. The application of the improved 3D rat testicular cells co-culture model on thein vitrotoxicity research of HZ1006
    Xiaofang Zhang, Zhu Yuping, Yijun Tian, Han Yan, Lijun Ren, Wenjing Shi, Zhu Jiangbo, Tianbao Zhang · 2018 · Drug and Chemical Toxicology
83. Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance
    Yun Dai, Steven Grant · 2011 · Humana Press eBooks
84. ER Stress Signaling in Alzheimer's Disease
    M. M. Rahman, Looniva Shrestha, Mst Ara Gulshan · 2020 · Advances in medical diagnosis, treatment, and care (AMDTC) book series
85. Activity of the histone deacetylase inhibitors LBH589 and LAQ824 in hematologic malignancies
    Kapil N. Bhalla · 2009 · Hematology Meeting Reports
86. HDAC inhibitor research: still in its infancy.
    Serena Tsan-Lai Wong, Mark N. Stein · 2010 · PubMed
87. New Therapies in Chronic Lymphocytic Leukemia
    John C. Byrd, Farrukh Tauseef Awan, Thomas S. Lin, Michael R. Grever · 2008 · CRC Press eBooks
88. Drugging the Hsp90 molecular chaperone machine for cancer treatment
    Joanna L. Holmes, Swee Y. Sharp, Paul Workman · 2007 · Springer eBooks
89. Phosphorylation of Histone Deacetylase 6 within its C-terminal Region by Extracellular Signal Regulated Kinase 1
    Kendra A. Williams · 2013 · Digital Commons - University of South Florida (University of South Florida)
90. The Role of Heat Shock Protein 90 as a Therapeutic Target for Multiple Myeloma
    Constantine S. Mitsiades, Teru Hideshima, Nikhil C. Munshi, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2008 · Humana Press eBooks
91. The Impact of Molecularly Targeted Therapy in Multi-Modality Therapy
    Shiyu Song, Paul Dent, Steven Grant · 2009 · Medical radiology
92. Roles of Cytoplasmic Deacetylase Hdac6 in Oncogenic Tumorigenesis
    Yishan Lee · 2008 · DukeSpace (Duke University)
93. Targeting Ectopic Hsp90 in Breast Cancer
    Jared James Barrott · 2014
94. Emerging Therapeutics for AML
    Edward A. Sausville · 2007 · Humana Press eBooks
95. Targeting HER-2 Signaling Network: Implication in Radiation Response
    In Ah · 2011 · InTech eBooks
96. Development and validation of a LC‐MS assay for the quantification of ikh12 a novel anti‐tumor candidate in rat plasma and tissues and its application in a pharmacokinetic study
    Dorleta Otaegui, Carme Masdeu, Eneko Aldaba, Yosu Vara, Aizpea Zubia, Eider San Sebastián, Maria Alcalá, Sergio Villafruela, Fernando Pedro Cossío, Alicia Rodríguez‐Gascón · 2015 · Biomedical Chromatography
97. Combinations of Novel Histone Deacetylase and Bcr-Abl Inhibitors in the Therapy of Imatinib Mesylate-Sensitive and Refractory Bcr-Abl Expressing Leukemia
    Kapil N. Bhalla · 2007
98. Potential of Heat Shock Protein Targeting for Human Therapy
    Laszlo Jr Otvos · 2011
99. Histone Deacetylase Inhibitors: A Brief Overview Of Their Role And Medicinal Chemistry
    Patrick R. Angibaud, Kristof Van Emelen, Janine Arts · 2010 · Wiley eBooks
100. Recovery of Genes Epigenetically Altered by the Histone Deacetylase Inhibitor Scriptaid and Demethylating Agent 5-Azacytidine in Human Leukemia Cells
     Eunkyung Park, Eun Hyung Jeon, In-Ho Kim, Seonyang Park · 2010 · Genomics & Informatics